


CLAIMS

What is claimed is:

1. A method of treating, suppressing or inhibiting a proliferative disease in a subject comprising the step of administering to said subject a composition comprising one or more compounds
5 represented by the structure of Formula (I):



and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

10 R₃ is H, -CH₃ or R_x;

R₄ is H or R_y;

R_x

is: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((CH(

CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH₂--OP(O)(OH)₂,
,
 or -CH₂OC(O)--CH₂OP(O)(OH)₂;

15 R_y is: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OH₃,

or -SCH₂CH(NH₂)C(O)OC(CH₃)₃;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,

20 cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;

each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;


y is zero, 1 or 2; and

z is zero, 1, or 2

wherein said composition is administered at a dose of 4 mg.


- 25 2. The method of claim 1, wherein said proliferative disease is a pre-cancerous condition or a benign proliferative disorder.

3. The method of claim 1, wherein said proliferative disease is a cancer.
4. The method of claim 3, wherein said cancer comprises Adenoid Cystic Carcinoma (ACC).
5. The method of claim 3, wherein said cancer comprises a lymphoma.
6. The method of claim 5, wherein said lymphoma comprises Marginal zone B cell lymphoma,
5 Diffuse large B cell lymphoma, Mantle cell lymphoma, or a combination thereof.
7. The method of claim 3, wherein said cancer comprises breast cancer.
8. The method of claim 7, wherein said breast cancer comprises triple negative breast cancer
9. The method of claim 3, wherein said cancer comprises endometrial cancer.
10. The method of claim 3, wherein said cancer comprises non-small cell lung cancer (NSCLC).
- 10 11. The method of claim 3, wherein said cancer comprises multiple myeloma.
12. The method of claim 3, wherein said cancer comprises leukemia.
13. The method of claim 12, wherein said leukemia comprises T-cell acute lymphoblastic
leukemia (T-ALL), T-lymphoblastic leukemia/lymphoma (TLL), or Chronic Lymphocytic
Leukemia (CLL).
- 15 14. The method of claim 3, wherein said cancer comprises a Desmoid tumor.
15. The method of any one of claims 3-14, wherein said cancer comprises a Notch-activating
mutation, a Wnt-activating mutation, or a combination thereof.
16. The method of any one of claims 1-15, wherein said composition is administered as a
monotherapy.
- 20 17. The method of any one of claims 1-15, wherein said composition further comprises a second
composition comprising an additional cancer therapeutic agent.
18. The method of any one of claims 1-17, wherein said first composition and/or said second
composition is intravenously administered to said subject.
19. The method of any one of claims 1-17, wherein said first composition and/or said second
25 composition is orally administered to said subject.
20. The method of any one of claims 17-19, wherein said first composition and said second
composition are administered together.
21. The method of any one of claims 17-19, wherein said first composition and said second
composition are administered at separate sites or at separate times.
- 30 22. The method of claim 21, wherein said first composition comprising Formula (I) is administered
prior to and then again subsequent to the administration of said second composition comprising
said additional cancer therapeutic agent.
23. The method of any one of claims 1-22, wherein the compound of Formula (I) comprises:




(1)

24. The method of any one of claims 1-22, wherein the compound of Formula (I) comprises:



(2)

25. The method of any one of claims 1-22, wherein the compound of Formula (I) comprises:



(22).


26. The method of any one of claims 1-25, wherein said additional cancer therapeutic agent comprises one or more inhibitors of mammalian target of rapamycin (mTOR) and cisplatin.

27. The method of claim 26, wherein said mTOR inhibitor comprises Everolimus.

28. The method of any one of claims 1-27, wherein said composition is administered once per week.

29. The method of any one of claims 1-28 wherein said composition is administered once every two weeks.


30. A method of treating, suppressing or inhibiting a solid tumor in a subject comprising the step of administering to said subject a composition comprising the compound of Formula (1):



(1),

wherein said compound is administered to said subject intravenously at a dose of 4 mg once per week.

31. The method of claim 30, wherein said solid tumor comprises Adenoid Cystic Carcinoma (ACC).
32. The method of claim 30, wherein said solid tumor comprises triple negative breast cancer (TNBC), non-TNBC breast cancer, colorectal cancer, Desmoid/fibromatosis, Gastric cancer, Melanoma, non-small cell lung cancer (NSCLC), squamous, NSCLC, non-squamous, or ovarian cancer.
33. The method of claim 30, wherein said solid tumor comprises gastroesophageal junction adenocarcinoma.
34. The method of claim 30, wherein said solid tumor comprises chronic lymphocytic leukemia (CLL), Marginal zone B cell lymphoma, Diffuse large B cell lymphoma, Mantle cell lymphoma, or a combination thereof.
35. The method of claim 30, wherein said solid tumor comprises a Desmoid tumor.
36. The method of any one of claims 30-35, wherein said solid tumor comprises a Notch-activating mutation.
37. A method of treating, suppressing or inhibiting a solid tumor in a subject comprising the step of administering to said subject a composition comprising the compound of Formula (1):



(1),

wherein said compound is administered to said subject intravenously at a dose of 6 mg once every two weeks.

38. The method of claim 37, wherein said solid tumor comprises Adenoid Cystic Carcinoma (ACC).

39. The method of claim 37, wherein said solid tumor comprises triple negative breast cancer (TNBC), non-TNBC breast cancer, colorectal cancer, Desmoid/fibromatosis, Gastric cancer, Melanoma, non-small cell lung cancer (NSCLC), squamous, NSCLC, non-squamous, or ovarian cancer.
- 5 40. The method of claim 37, wherein said solid tumor comprises gastroesophageal junction adenocarcinoma.
41. The method of claim 37, wherein said solid tumor comprises chronic lymphocytic leukemia (CLL), Marginal zone B cell lymphoma, Diffuse large B cell lymphoma, Mantle cell lymphoma, or a combination thereof.
- 10 42. The method of claim 37, wherein said solid tumor comprises a Desmoid tumor.
43. The method of any one of claims 37-42, wherein said solid tumor comprises a Notch-activating mutation.